This research demonstrates improved delivery of felodipine in a gel-based formulation, indicating enhanced neuroprotection in Alzheimer's disease.
Background Felodipine (FLD) is a L-type calcium channel blocker with pronounced neuroprotection against Alzheimer's disease (AD). Unfortunately, the efficacy of FLD has been impeded by limited solubility, poor bioavailability, and sub-optimal accumulation. Thus, the current study unfolds the potential of nanostructured lipid carriers based on in-situ gel of FLD (FLD-NLCs gel) to ameliorate dementia.
No takes yet. Share an insight, caveat, or question.
Jog et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: